InsiderCluster

IBRX

NasdaqGS

ImmunityBio, Inc.

$7.17
-0.28 (-3.76%)

Price

-4.34% over 1D

Key statistics

Previous close$7.45
Day range7.10 – 7.62
52-week range1.95 – 12.43
Volume9.37M
CurrencyUSD
ExchangeNasdaqGS
Crowd sentiment
100Bullish

Insider activity

SEC EDGAR ↗
Open-mkt buys
0
$0.00
Open-mkt sells
5
$3,754,130.21
Net flow
3.75M
5 open-market trades

Showing 27 recent filings. 22 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.

InsiderTypeSharesPriceValueDate
Cohen Cheryl
Director
Option exercise55.98K$2.98$166,817.422026-07-02
Cohen Cheryl
Director
Sell (open market)131.21K$9.50$1,246,941.112026-07-02
Cohen Cheryl
Director
Option exercise55.98K$0.002026-07-02
Selecky Christobel
Director
Option exercise35.06K$2.98$104,490.722026-07-01
Selecky Christobel
Director
Option exercise124.41K$2.99$371,997.862026-07-01
Selecky Christobel
Director
Sell (open market)159.48K$9.02$1,439,065.682026-07-01
Selecky Christobel
Director
Option exercise35.06K$0.002026-07-01
Selecky Christobel
Director
Option exercise124.41K$0.002026-07-01
Selecky Christobel
Director
Option exercise32.17K$2.98$95,875.542026-06-29
Selecky Christobel
Director
Option exercise33.55K$2.99$100,311.512026-06-29
Selecky Christobel
Director
Option exercise30K$2.84$85,200.002026-06-29
Selecky Christobel
Director
Sell (open market)95.72K$9.01$862,215.922026-06-29
Selecky Christobel
Director
Option exercise700$2.98$2,086.002026-06-30
Selecky Christobel
Director
Option exercise300$2.99$897.002026-06-30
Selecky Christobel
Director
Sell (open market)1K$9.00$9,000.002026-06-30
Selecky Christobel
Director
Option exercise32.17K$0.002026-06-29
Selecky Christobel
Director
Option exercise33.55K$0.002026-06-29
Selecky Christobel
Director
Option exercise30K$0.002026-06-29
Selecky Christobel
Director
Option exercise700$0.002026-06-30
Selecky Christobel
Director
Option exercise300$0.002026-06-30
Simon Barry J.
Director
Sell (open market)25K$7.88$196,907.502026-06-24
BLASZYK MICHAEL D
Director
Grant / award65.6K$0.002026-06-09
Wendel Bruce
Director
Grant / award65.6K$0.002026-06-09
MAXWELL LINDA
Director
Grant / award65.6K$0.002026-06-09
Clark Wesley
Director
Grant / award65.6K$0.002026-06-09
Cohen Cheryl
Director
Grant / award65.6K$0.002026-06-09
Selecky Christobel
Director
Grant / award65.6K$0.002026-06-09

Source: SEC EDGAR Forms 4/4A (CIK 1326110). Click an insider to open the original filing.

Social sentiment

100
Bullish

Volume-weighted across live social sources

StockTwitsLIVE
5 bull1000 bear
Recent posts
@PeelonDusk· StockTwits1d ago

$IBRX 1. The Core Scientific Analogy: Why "The Next Keytruda"? Keytruda (PD-1 Inhibitors) = "Taking Off the Brakes": Keytruda blocks the signal that cancer cells use to hide from T-cells. However, Keytruda only works if the patient already has an active pool of killer T-cells present inside a "hot" tumor. If the tumor is "cold" or the immune system is depleted (lymphopenia), Keytruda fails. ANKTIVA (IL-15 Superagonist) = "Stepping on the Gas": ANKTIVA actively proliferates, recruits, and activates Natural Killer (NK) cells and memory CD8+ T-cells without expanding suppressive regulatory T-cells. The PSS Thesis: By combining ANKTIVA with existing checkpoint inhibitors, chemotherapy, or cell therapies, ANKTIVA can convert treatment-resistant "cold" tumors into "hot" tumors. If proven across multiple tumor types, ANKTIVA becomes an indispensable combination backbone therapy that major pharmaceutical companies and insurers must adopt across oncology.

@IBBullish· StockTwits1d ago

$IBRX one more red day on Monday before a possible Green Day if earnings are good and announced on Tuesday. If not, 2 more red days.

@LB19· StockTwits1d ago

$IBRX 😡😭 Let patients have access, let them have a choice.

@kcajsnikrep· StockTwits1d ago

$IBRX There are still 3.5 hours of July left on the West Coast. Enough time for that Global Expansion “leapfrog” announcement!

@todn· StockTwits1d ago

$IBRX IBRX has repeatedly shown multi-day upside after positive press releases, with the initial reaction often followed by further gains as the news digests and shorts cover. Examples: • July 29, 2026 (UAE approval): $6.83 → $7.45 the next day (+9%) • Feb 23, 2026 (FY results + global/lung approvals): $8.70 → $11.55 over two sessions (+33%) • May 19, 2026 (FDA sBLA acceptance): ~8% rise in the following session High short interest and accumulation dynam

@LB19· StockTwits1d ago

$IBRX I'm only speculating here. If there was a partership in the works, especially if a company stake in negotiation wouldn't there be non-disclosure agreements in place hushing up Dr. Patrick until everything is final? That would explain why Dr. Patrick has been more quiet. All the Leonardo updates, photos etc stopped. Pumping things like NK world bank stopped. Dr. Patrick is even sitting on a documentary covering his patients like Lori's husband, she has been saying she doesn't understand why it hasn't been released yet. Am just openly speculating trying to find understanding to what we've been observing. Dr. Patrick dropped a clue when he said: " I will NEED somebody to help me maneuver through that opportunity where we go global and change the world on that basis " "Need somebody" as in he is not going to go at this alone.

@BullriderNkg· StockTwits1d ago

$IBRX So the Saudis and now the UAE are on board. For the Saudis, I hope they bought something in Q 2. We can look to Q3 for both the Saudis and UAE. Real sales from both of these countries will be critical!!!

@DannyMac56· StockTwits1d ago

$IBRX

@LB19· StockTwits1d ago

$IBRX "global expansion unstoppable" is not going to come from a deal or an announcement. Global expansion unstoppable is because ALC matters and we have the answer. Humanity may have overlooked ALC because there wasn't an answer but it is here now. UAE news is about the validation more than anything else. That yes lymphocytes matter! That ALC is not just a number! It can make a difference for lung patients! It's a paradigm shift, the best we can do is keep a spotlight on everything. I personally think the patient experiences can be the fundamental driving force to rapidly bring about awareness and change. We must value ALC and make it a priority. All cancer patients should have strong lymphocytes levels be made a priority immediately upon cancer diagnosis.

@Whatever2020· StockTwits1d ago

$IBRX Bobthebagholder had to go into the simpleton bin with over 100 of his fellow psychopaths. Thank God for the nut bin button.

@Biofrog· StockTwits1d ago

$IBRX I think the surprise coming before end of year is Lymphopenia approval. IMO Trump will push it with the new Management.

@Biofrog· StockTwits1d ago

$IBRX It's all very cool. We are good. Anktiva and the Leonardo cells will kill the competition.

Latest news

Get insider-buy alerts

Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.